Huay-Keng Loke

Huay-Keng Loke has a diverse work experience in the field of biochemistry and structural sciences. In 2002, they worked as a Postdoctoral Biochemist at Ambion, and from 2003 to 2005, they served as a Postdoctoral Scientist at Rockefeller University. In 2006, Loke joined Millennium, the Takeda Oncology Company, where they worked as a Scientist and later progressed to the role of Senior Scientist until 2018. From 2018 to 2022, they worked at Cedilla Therapeutics as a Principal Scientist and later as a Senior Principal Scientist. In 2022, Loke joined Roivant Discovery as a Director of Biochemistry before moving to Covant Therapeutics, where they currently hold the position of Director of Biochemistry and Structural Sciences.

Huay-Keng Loke obtained a Ph.D. in Chemistry from Texas A&M University from 1996 to 2001.